Genetic testing study for breast cancer DNA repair changes
Part of Cancer, Skin clinical trials.
This study looks at which DNA “repair” gene changes are found in breast cancer patients, especially certain subtypes and high-risk situations. Your genetic test results may help researchers understand who has specific DNA repair pathway mutations and how they relate to breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer confirmed by pathology (a tissue/biopsy diagnosis).
- You fit at least one group: triple-negative breast cancer, age 50 or younger, male breast cancer, or certain personal/family cancer history.
- You are HER-2 negative (either recurrent/metastatic or high-risk).
- You have been (or plan to be) tested for germline and/or tumor (somatic) DNA repair gene mutations.
- You can share your medical records and the results of DNA repair gene testing, and agree to longer-term follow-up.
- Your study team can see your DNA repair gene testing results; you cannot be missing those results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This study tests the genes of your cancer to learn more about advanced breast, lung, melanoma, or sarcoma tumors. It may help doctors find better ways to treat these cancers in the future.
This trial looks for specific DNA repair changes in men with prostate cancer. It tests if these genetic features can help guide treatment decisions. You may join if you have high-risk localized, newly metastatic, or advanced prostate cancer and have tissue available for testing.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.